🏛️ Verified NIH Record • Updated 2026-06-19
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT04161248)
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Canadian Cancer Trials Group
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Who can join: Review the eligibility criteria below.
Location: BCCA - Vancouver — Vancouver, British Columbia
Age range: 16 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- BCCA - Vancouver — Vancouver, British Columbia
- Kingston Health Sciences Centre — Kingston, Ontario
- University Health Network — Toronto, Ontario
- The Jewish General Hospital — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.